Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population‐based nationwide study

• Main Authors: Annalisa Trama, Claudia Proto, Diego Signorelli, Marina C. Garassino, Giuseppe Lo Russo, Monica Ganzinelli, Arsela Prelaj, Carolina Mensi, Manuela Gangemi, Valerio Gennaro, Elisabetta Chellini, Adele Caldarella, Italo F. Angelillo, Valeria Ascoli, Cristiana Pascucci, Giovanna Tagliabue, Rosanna Cusimano, Francesca Bella, Fabio Falcini, Enzo Merler, Giuseppe Masanotti, Antonio Ziino, Maria Michiara, Gemma Gola, Cinzia Storchi, Lucia Mangone, Maria F. Vitale, Claudia Cirilli, Rosario Tumino, Tiziana Scuderi, Anna C. Fanetti, Silvano Piffer, Marcello Tiseo, Gemma Gatta, Laura Botta, the LUME study WG
• Format: Article
• Language: English
• Published: Wiley 2020-06-01
• Series: Thoracic Cancer
• Subjects: Logistic models; mesothelioma malignant; registries; therapeutics
• Online Access: https://doi.org/10.1111/1759-7714.13456

Abstract Background Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. Centralization of rare cancer in dedicated centers is recommended to ensure expertise, multidisciplinarity and access to innovation. In Italy, expert centers for MPM have not been identified in all regions. We aimed to describe the treatment patterns among MPM patients across different Italian regions and to identify factors associated with the treatment patterns across the regions. Methods We performed an observational study on a random sample of 2026 MPM patients diagnosed in 2003–2008. We included 26 population‐based registries covering 70% of the Italian population. To identify factors associated with treatment patterns, across the different regions, we fitted a multinomial logistic regression model adjusted by age, sex, stage, histology and hospital with thoracic surgical department. Results MPM patients mostly received chemotherapy alone (41%) or no cancer‐directed therapy (36%) especially the older patients. The first course of treatment for MPM patients differed across regions. Patients from Piedmont, Liguria and Campania were more likely to receive no cancer‐directed therapy; those living in Tuscany and Sicily were more likely to get surgery; patients from Marche and Lazio were more likely to receive chemotherapy. These differences were not explained by age, sex, stage, histology and availability of a thoracic surgery department. Conclusions There is limited expertise available and lack of a network able to maximize the expertise available may contribute to explaining the results of our study. Our findings support the need to ensure the appropriate care of all MPM patients in reorganizing the health care services. Key points Significant findings of the study: MPM patients mostly received chemotherapy alone or no cancer‐directed therapy especially the older patients. The first course of treatment for MPM patients differed across Italian regions. What this study adds: Differences in MPM clinical management are not explained by the age, stage, histology nor by the availability of a thoracic surgery department. Limited expertise for MPM contribute to explaining the unequal access to appropriate care for MPM patients in Italy.